ClinicalTrials.gg
TerminatedNCT04601610Updated Oct 28, 2022

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

A Phase 1/2 interventional study of KN046 (PD-L1/CTLA4 BsAb) and Ningetinib Tosylate(multi-target TKI) in Advanced HCC, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Terminated at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-10-28.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The sponsor's development strategy adjustment resolution is terminated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study is an open, multi-center clinical trial, the purpose is to study the safety and preliminary efficacy of KN046 combined with Ningatinib in subjects with advanced hepatocellular carcinoma.

Read the detailed description

The study consists of dose escalation and dose expansion, the mTPI-2 (Modified Toxicity Probability Interval) will be used for dose exploration. The preset dose of KN046 is 5 mg/kg Q3W and the preset dose of ningatinib is 10 mg (rapid titration), 20 mg QD, 30 mg QD, and 40 mg QD.Dose expansion will be divided into two cohorts, cohort 1 will enroll subjects who have not received system therapy and cohort 2 will enroll subjects who have previously received at least first-line system therapy.

02

Conditions studied

  • Advanced HCC
03

In context

Lead sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd is the lead sponsor of 38 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of hepatocellular carcinoma confirmed by histology or cytology;
  • Barcelona Clinic Liver Cancer (BCLC) Stage B or C;
  • performance status: 0-1;
  • score≤7;
  • Enough organ function;
  • Has at least one based on 1.1;
  • ≥3 months;
  • Patients must be able to understand and willing to sign a written document;

Exclusion criteria

Exclusion Criteria:

  • Fibrous lamina hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma etc;
  • Past or present hepatic encephalopathy; or Budd-Chiari syndrome; or Tumor thrombus invasion at the main portal vein (Vp4), inferior vena cava or heart involvement;
  • Subjects who have previously received (such as anti-PD-1/L1, CTLA-4, etc.); or have a history of ≥ grade 3 immune-related adverse reactions; or hyperprogressive after immunotherapy previously;
  • Subjects who have received liver local treatment (transcatheter chemoembolization, transcatheter embolization, hepatic artery perfusion, radiotherapy, radioembolization or ablation) within 4 weeks before administration;
  • Subjects who need or agents for systemic therapy;
  • Any previous or current active disease or history of autoimmune disease;
  • History of liver transplantation;
  • History of interstitial lung disease or non-infectious pneumonia;
  • History of allergic reactions to related drugs;
  • \< 50% or LLN
  • Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients undergoing total gastrectomy;
  • With serious systemic diseases such as heart disease and cerebrovascular disease, and the condition is unstable or uncontrollable;
  • Subjects with gastrointestinal bleeding or thrombosis or embolic events within 6 months;
  • Untreated hepatitis infection: >2000IU/ml or10000 copies/ml, > 1000copy/ml, both HbsAg and anti-HCV body are positive;
  • Evidence of active pulmonary tuberculosis (TB);
  • Positive test of immunodeficiency virus () or acquired immunodeficiency syndrome (AIDS);
  • Pleural effusion, ascites and pericardial effusion with clinical symptoms or needing drainage;
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Subjects who have not received first-line system treatment previously;

    Drug: KN046 (PD-L1/CTLA4 BsAb) · Drug: Ningetinib Tosylate(multi-target TKI)

  • Experimental
    Cohort 2

    Subjects who have received at least first-line system treatment

    Drug: KN046 (PD-L1/CTLA4 BsAb) · Drug: Ningetinib Tosylate(multi-target TKI)

Interventions

  • DrugKN046 (PD-L1/CTLA4 BsAb)

    KN046 5mg/kg Q3W

  • DrugNingetinib Tosylate(multi-target TKI)

    ningtinib QD, dose will be decided by investigator

06

What researchers measure

Primary outcomes

  1. DLT

    Dose limit toxicity

    Time frame: 1 months

  2. ORR

    objective response rate (ORR) based on the RECIST 1.1 by investigator

    Time frame: 1 years

Secondary outcomes

  1. PFS

    progression free survival

    Time frame: 1.5 years

  2. OS

    overall survival

    Time frame: 3 years

07

Study locations

1 site
  • Chinese Pla General Hospital Chinese Pla Medical School
    Beijing, Beijing 100071, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in May 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2020
First posted
Oct 26, 2020
StartActual
Jun 7, 2021
Primary completionActual
May 30, 2022
CompletionActual
May 30, 2022
Last update
Oct 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04601610
Responsible party
Sponsor
First posted
Oct 26, 2020
Start date
Jun 7, 2021
Primary completion
May 30, 2022
Completion
May 30, 2022
Last update
Oct 28, 2022

Study contacts

JianMing Xu, Doctor
principal investigator · 301 Hospital of PLA,Beijing,China
ShanZhi Gu, Doctor
principal investigator · Hunan Cancer Hospital
YuXian Bai, Doctor
principal investigator · Harbin Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion